Draflazine

• Description :

  Draflazine (R-75231) is a ENT1 inhibitor. Draflazine (R-75231) completely reverses the hypersensitivity in the complete Freund’s adjuvant (CFA) model of mechanical hyperalgesia and the carrageenan inflammation model of thermal and mechanical hyperalgesia[1].

• CAS Number :

  [120770-34-5]

• Product Name Alternative :

  R-75231; R88021

• UNSPSC :

  12352005

• Target :

  Adenosine Receptor; Nucleoside Transporters

• Type :

  Reference compound

• Related Pathways :

  GPCR/G Protein; Membrane Transporter/Ion Channel

• Applications :

  COVID-19-immunoregulation

• Field of Research :

  Inflammation/Immunology

• Assay Protocol :

  https://www.medchemexpress.com/draflazine.html

• Purity :

  99.06

• Solubility :

  DMSO : 100 mg/mL (ultrasonic)

• Smiles :

  O=C(NC1=C(Cl)C=C(N)C=C1Cl)CN2C(C(N)=O)CN(CCCCC(C3=CC=C(F)C=C3)C4=CC=C(F)C=C4)CC2

• Molecular Formula :

  C30H33Cl2F2N5O2

• Molecular Weight :

  604.52

• References & Citations :

  [1]Maes SS, et al. Antihyperalgesic activity of nucleoside transport inhibitors in models of inflammatory pain in guinea pigs. J Pain Res. 2012;5:391-400.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  Phase 2